-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Barchart·08/06/2026 06:30:00
Listen to the news

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 

NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completion

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.